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Abstract: Prader–Willi syndrome (PWS) is a complex neurodevelopmental disorder caused 
by an abnormality on the long arm of chromosome 15 (q11–q13) that results in a host of 
phenotypic characteristics, dominated primarily by hyperphagia and insatiable appetite. Char-
acteristic behavioral disturbances in PWS include excessive interest in food, skin picking, 
difficulty with a change in routine, temper tantrums, obsessive and compulsive behaviors, and 
mood fluctuations. Individuals with PWS typically have intellectual disabilities (borderline to 
mild/moderate mental retardation) and exhibit a higher overall behavior disturbance compared to 
individuals with similar intellectual disability. Due to its multisystem disorder, family members, 
caregivers, physicians, dieticians, and speech-language pathologists all play an important role 
in the management and treatment of symptoms in an individual with PWS. This article reviews 
current research on behavior and cognition in PWS and discusses management guidelines for 
this disorder.
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Introduction
First described in 1956 by Prader, Labhart, and Willi, Prader–Willi syndrome (PWS) is 
a complex neurodevelopmental disorder that affects approximately 1 in 20,000 births 
with no distinguishing sex, race, or social status association.1 Individuals with PWS 
are typically short, obese, possess small hands and feet, and have dysmorphic features 
such as a narrow bifrontal diameter, full cheeks, and almond shaped eyes.2 In the 
neonatal period, diminished fetal activity, hypotonia, and feeding difficulty persist 
followed by hyperphagia, delayed psychomotor development, early onset obesity, 
incomplete sexual development in adolescence, sleep apnea, intellectual disabilities, 
and a behavioral profile that includes obsessive, compulsive, oppositional, and defiant 
behaviors.3 Individuals with PWS typically have intellectual disabilities (borderline to 
mild/moderate mental retardation) and exhibit a higher overall behavior disturbance 
compared to individuals with intellectual disability of unknown etiology.4 Due to 
the combination of hypotonia and intellectual disabilities, individuals with PWS also 
have speech and language difficulties.5 Risk factors for mortality in PWS include severe 
obesity, obstructive sleep apnea, upper respiratory tract infections (URI), aspiration, 
and tonsilor/adenoid hypertrophy.6 While those with intellectual disability (ID) have 
a higher mortality rate than in the general population, Einfeld and colleagues found 
that individuals with PWS have six times greater risk of death than other individuals 
with ID with obesity being the greatest risk factor.7Neuropsychiatric Disease and Treatment 2010:6 108
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PWS is caused by the absence of expression of the 
paternally active genes in the proximal arm of chromosome 15. 
Approximately 70% of the cases are due to the deletion of the 
paternally inherited chromosome 15 (q11–q13 region), 25% 
due to maternal uniparental disomy (m-UPD) of chromosome 
15, and the rest are due to either a methylation imprinting 
defect or a translocation microdeletion.8–10 Individuals with 
paternal deletion can be further subdivided into Type I dele-
tions (involving breakpoints BP1 and BP3 and is relatively 
longer – approximately 5 MB in size) and Type II dele-
tions (involving breakpoints BP2 and BP3 and is relatively 
shorter – approximately 500 kb smaller).11 Diagnostic criteria 
for PWS, which includes an inclusive listing of symptoms 
and a scoring system, was first developed in 1993 and still 
remains useful in informing and raising detection of the 
syndrome.2 However, cytogenetic and molecular techniques 
are used to confirm diagnosis. Fluorescent in situ hybridiza-
tion (FISH), a cytogenetic technique that can identify and 
localize the presence or absence of specific DNA sequences 
on chromosomes, detects nearly all persons with deletions 
in the 15 (q11–q13 region).12 Additionally DNA methylation 
analysis detects methylation pattern characteristics with a 
sensitivity and specificity of nearly 100%.13 Current recom-
mendation is for all newborns with persistent hypotonia to 
first undergo methylation analysis to test for PWS.14,15 If meth-
ylation analysis is positive, a FISH test should be performed 
to ascertain whether PWS is caused by paternal deletion or 
m-UPD.15 While certain features of PWS are highly prevalent 
across genetic subtypes, recent research suggests that the 
deletion or m-UPD genetic subtypes may exhibit different 
risks for psychotic disorders.16–18 Furthermore, they may 
not exhibit problem behaviors with the same frequencies or 
severities.19–21
Behavior and cognition
Considered to have a specific behavioral phenotype,22,23 
typical behavioral disturbances in PWS include excessive 
interest in food, skin picking, difficulty with change in rou-
tine, temper tantrums, obsessive and compulsive behaviors, 
and mood fluctuations.24–27 Older children and adults with 
PWS exhibit elevated compulsions as measured by the com-
pulsivity subscale of the Yale–Brown Obsessive Compulsive 
Scale.28,29 When compared with other children with devel-
opmental delay, 2–7 year-old children with PWS engage in 
more compulsive behaviors, and these behaviors are related to 
the severity of hyperphagia symptomatology.30 The obsessive 
and compulsive behaviors found in PWS tend to be ritualistic 
behaviors such as hoarding, ordering and arranging objects, 
insistence on routines, and repetitive speech, rather than the 
more common symptoms found in obsessive-compulsive dis-
order (OCD) such as checking and cleaning or preoccupations 
with sexual, religious, or aggressive impulses.31 Furthermore, 
unlike OCD, those with PWS do not appear to perform ritual-
istic behaviors aimed at reducing their anxiety or discomfort 
but may do so because it is enjoyable.32 Interestingly, the 
types of repetitive behaviors seen in PWS are similar to those 
common in autism spectrum disorders (ASD).31,33,34 Recent 
evidence suggests that there may be increased prevalence of 
ASD diagnosis in PWS (see Dimitropoulos and Schultz31 for 
recent review) with a specific elevated risk in PWS m-UPD 
cases.35 The symptoms of autism are believed to be caused by 
many genes on multiple chromosomes, but one of the most 
frequent genetic abnormalities resides on the same criti-
cal region for PWS, Chromosome 15(q11–q13).36,37 While 
individuals with the m-UPD genotypic subtype may be at 
an increased risk for autistic symptomatology, psychosis, 
and sleep disorders,16 those with the deletion subtype have 
greater rates of skin picking, distress, mood lability, food 
stealing,38 withdrawal, sulking, nail biting, hoarding, and 
overeating.19 High rates of attention-deficit hyperactivity 
disorder (ADHD) symptoms, insistence on sameness, and 
their association with maladaptive conduct problems have 
also been reported with severity being more pronounced 
in individuals with paternal deletion relative to those with 
m-UPD.17 Regardless of genetic subtype, weaknesses have 
been shown in socialization in addition to a relative strength 
in daily living skills that may be due to heightened interest 
in food and food preparation.23
Many individuals with PWS need psychiatric support 
during several periods of their lives when dealing with 
compulsions, depression, or psychotic episodes. Previous 
studies have shown that 6%–28% of individuals with PWS 
exhibited psychotic symptoms with an age of onset rang-
ing from 13 to 26 years and a prevalence rate higher than 
individuals with other IDs.18,22,39,40 Furthermore, individu-
als with PWS show age-related increases in internalizing 
problems such as anxiety, sadness, and a feeling of low self-
worth.41 Recent studies have found an association between 
m-UPD and psychotic illness.16,18,39 Boer and colleagues16 
found that the m-UPD subtype of PWS had more severe 
psychotic disorders than those with the deletion subtype of 
PWS. While those with the deletion subtype of PWS have 
less severe psychotic disorders, gender has been shown to 
be significantly related to maladaptive behavior in those 
with PWS deletion.42 Males with the deletion subtype are at 
greater risk for aggressive behavior, depression, dependent Neuropsychiatric Disease and Treatment 2010:6 109
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personality disorder, and overall severity of psychopathology 
than females with PWS deletion.42 Recent research has 
aimed to further specify the PWS phenotype by exploring 
differences between Type I and Type II deletions. Butler 
et al reported lower adaptive behavior scores in individuals 
with Type I deletion and greater externalizing behaviors and 
more severe compulsions in individuals with Type II dele-
tions.43 Hartley and colleagues indicated people with Type I 
deletion had significantly higher Reiss depression (physical 
signs) scores than people with Type II deletion.42 In addition, 
Zarcone and colleagues found more washing/cleaning com-
pulsions in those with Type I deletions and more rereading 
and rewriting compulsions in those with Type II deletions.44 
However, these results have yet to be replicated. Milner and 
colleagues found differences between Type I deletion and 
Type II deletion to be minimal although people with Type I 
deletion performed more poorly on all measures of ability.45 
In a more recent study, Dykens and Roof found no differences 
between deletion subtypes.11
Cognitively, most individuals with PWS function in the 
mild mental retardation range with a mean IQ in the 60s to 
low 70s.46,47 However, regardless of measured IQ, many of 
these individuals cannot perform at their predicted IQ score 
in everyday functioning if their emotional and behavioral 
problems are left untreated.48 The combination of food-related 
preoccupations and numerous maladaptive behaviors makes 
it difficult for individuals with PWS to perform to their IQ 
potential. Compared to individuals with ID, those with PWS 
show a distinctive profile of cognitive strengths and weak-
nesses.49,50 Short-term memory is more severely affected than 
long-term memory51,52 while deficits in auditory processing 
is more pronounced than visual processing.53 Deficits in 
executive tasks have also been observed.48,50 Individuals with 
PWS also have difficulty interpreting social information. In 
the Social Attribution Task, individuals with PWS performed 
significantly worse than an IQ-matched group and on par with 
individuals with pervasive developmental disorders.54
Previous research suggested that individuals with PWS 
may have had strengths in visuospatial ability due to their 
adept puzzle skills.46,55 However, new findings suggest this 
may not be true.56 While past research used visuospatial 
tasks resembling puzzles, Verdine and colleagues56 used 
tasks testing visuospatial ability used in typically developing 
populations: spatial perception, mental rotation, and spatial 
visualization.57 Verdine and colleagues56 found that individu-
als with PWS performed worse than the mental age matched 
group and thus, these abilities are not responsible for their 
jigsaw puzzle skills. While individuals with PWS on average 
tend to perform more poorly on visuospatial ability tasks 
compared to both mental age and chronological age matched 
controls,46,56 individuals with the deletion subtype of PWS 
appear to perform better at visual processing tasks than the 
m-UPD subtype.58 This relative sparing of visuospatial ability 
is not uniform though as the relative strength is seen only in 
the ventral stream (processes the surface characteristics of 
stimuli) and is accompanied by a deficit in the dorsal stream 
processing (processes position information in action).59 While 
Verdine and colleagues6 were not able to perform further 
subtype comparisons due to a limited sample size, it would 
be interesting to see if the pronounced, shape-based puzzle 
solving style in individuals with PWS was driven by the 
performance of the deletion subtype.
Research has also shown further differences in cognitive 
profile between the different genotypes. Whittington and 
colleagues20 found that individuals with m-UPD PWS had 
better verbal abilities, but poorer coding abilities than the 
deletion subgroup. This finding is consistent with the finding 
that the m-UPD PWS group has significantly higher verbal IQ 
scores than individuals with the deletion subtype of PWS.21 
Recent research examining differences between Type I and 
Type II deletions show that individuals with Type I deletions 
scored significantly lower on math and reading compared to 
individuals with Type II deletions.43
Speech and language development is often delayed 
and problematic in PWS.46,60,61 The severity differs greatly 
among individuals with PWS. There are those who are 
nonverbal and there are those who acquire normal speech 
and language by adulthood.5 In a typically developing 
child, word understanding essentially begins from birth and 
expressive language follows soon after at 3 months. By the 
age of 12 months, most children can say at least two words: 
“mama” and “dada.” On the other hand, children with PWS 
do not verbally display vocabulary until the age of 18 months 
and sometimes as late as 6 years.5 Common features seen in 
PWS include poor speech-sound development, reduced oral 
motor skills, and language deficits.60 In addition to speech 
difficulties, individuals with PWS may have language prob-
lems such as deficits in grammar, narrative abilities, and 
pragmatics.46,60 Poor speech-sound development of individu-
als with PWS may be a result of abnormal saliva (thick and 
viscous saliva),2 hypotonia, and cognitive deficits.5 Reduced 
oral motor skills, due to hypotonia, also contributes to poor 
speech-sound development as the rate of speech, quality 
of the voice, and the ability to articulate words is affected. 
With regard to language development, individuals with 
PWS frequently demonstrate poor receptive and expressive Neuropsychiatric Disease and Treatment 2010:6 110
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language skills, with expressive language showing greater 
deficits than receptive skills.5,61,62 Individuals with PWS 
also have poor narrative skills which negatively affect how 
they can communicate with others in both a social and work 
environment.5 These poor language skills may be the result 
of a deficit in auditory short-term memory,52 poor temporal 
sequencing skills,46 and poor auditory processing skills.5 In 
addition, individuals with PWS have difficulty maintaining 
a topic, showing appropriate empathetic speech, and turn 
taking in a conversation.5
Maladaptive behavior, cognitive impairment, and 
speech language development have important implications 
on the childhood and long-term functioning of an individ-
ual. Understanding the cognitive strengths and difficulties 
underlying the maladaptive behavior will allow for better 
management of the syndrome. One of the most significant 
stressors for family caregivers is the extent of emotional and 
behavioral problems exhibited by children and adults with 
developmental disabilities.63,64 Behavioral issues often impact 
individuals with PWS and their family more than any other 
aspect of the disorder. Therefore, it is important to not only 
manage and treat the most striking features of PWS such as 
hyperphagia and weight-related issues first, but to also be 
aware of the secondary behavioral and cognitive implications 
of behavioral therapy and medical treatments such as growth 
hormone and psychotropic medications.
Behavioral management
Due to the range of problems and variability of symptom 
severity across individuals with PWS, management of PWS 
is age-dependent, multidisciplinary, and utilizes a problem-
based approach to cater to each individual. While there is no 
cure for PWS, with early diagnosis and a proactive approach, 
individuals with PWS can live a full and meaningful life.
Early assessment and intervention by a speech-language 
pathologist is critical for developing future communica-
tion skills. Even in infancy, early intervention focusing on 
improving oral motor skills can improve feeding.5 Con-
tinued assessment of speech-sounds, receptive/expressive 
language skills, voice, and fluency is important throughout 
an individual’s life as each individual’s development may 
vary greatly from person to person.5 Therapeutic methods 
to improve articulation and language include exercises to 
improve muscle control of the mouth, tongue and throat, and 
techniques to improve pronunciation, increase vocabulary 
skills and sentence formation. In more severe cases of poor 
speech skills, other forms of communication such as sign 
language or communication boards may be helpful as an 
inability to communicate may lead to greater frustration and 
problem behaviors. Moreover, intervention should emphasize 
pragmatics along with managing behavioral problems as 
these maladaptive behaviors hinder satisfactory pragmatic 
language ability.
Management of behavioral problems is most effective 
if detected early as these difficulties may increase with age. 
Studies to date have shown the frequencies and severity of 
maladaptive behaviors are not uniform across age groups. 
Steinhausen and colleagues65 found that increased age was 
associated with higher scores on the DBC-P total behavior 
problem score (TBPS) along with the Disruptive/Antisocial, 
Communication Disturbance, Anxiety, and Social Relating 
subscales of the DBC-P. Age-related increases have also 
been found in the overall number of nonfood compulsive 
symptoms in individuals with PWS aged 5 to 47 years old.28 
In addition, Dykens and colleagues66 found that the fre-
quency of overeating, skin-picking, stubbornness, hoarding, 
ordering of items, and externalizing symptoms (tantrums, 
food theft and lying) increased with age in individuals with 
PWS in their teens, 20s, and 30s. Actually, those in their 
20s had the highest rate of maladaptive behaviors, social 
problems, and compulsive symptoms possibly due to new 
stressors such as transitioning from school to a work envi-
ronment and a more acute awareness of their differences 
relative to those of their same age.41 Adaptive behavior is 
often related to behavioral problems as individuals with 
an ID may engage in maladaptive behaviors as a means 
of communication.67 Moreover, research has shown that 
coping with stress, regulating negative affect, and resisting 
temptations require self-control, a limited and consumable 
resource.68 Thus, continuous self-control efforts, in addition 
to increased stress, will degrade the executive component 
of self-inhibition and over time lead to increased problem 
behaviors.
With regard to socialization in those with PWS, weakness 
has been shown in individuals aged under 30 years which 
may likely be due to inadequate coping skills.66 In fact, 
Hartley and colleagues42 found individuals with PWS aged 
20–29 years had significantly higher aggressive behavior 
scores than those aged 12–19 years and 30–45 years. The 
combination of adolescence and early adulthood being a 
period of emotional lability, independence seeking, and a 
period where difficulties with socialization abound as peers 
mature more rapidly makes this time especially challenging. 
In older adults, both maladaptive and compulsive behav-
iors, including noncompliance and skin picking, diminish 
significantly. This may be due to unknown physiological Neuropsychiatric Disease and Treatment 2010:6 111
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factors or the benefits of years of sustained behavior and 
dietary interventions.41 Furthermore, as individuals’ age, 
goals, preferences, motivation, and cognitive processes such 
as attention and memory change as they do in the general 
population.69 Whether or not there are distinct phenotypic 
changes in PWS during older adulthood has not been well 
researched.
Because food-related preoccupations and foraging may 
underlie behavior and emotional disturbances, food-related 
issues should be targeted and addressed first before behavioral 
management of nonfood-related issues becomes attain-
able.70 Given unrestricted access to food, those with PWS 
will consume approximately three times more calories than 
that of individuals matched on age and body mass index.71 
In addition, individuals with PWS show a strong preference 
for sweet foods rather than salty, plain, or sour foods72 and 
they also have a clear preference for high fat or carbohydrate 
foods to foods with lower caloric values.73,74 When food is 
unavailable, individuals with PWS may eat inedible food 
such as pet food due to abnormalities in satiety response 
and early returns of hunger after meals.75–77 If overeating 
is uncontrolled, it may lead to life-threatening obesity and 
increase risk for multiple medical conditions such as Type 2 
diabetes, respiratory problems, and cardiovascular disease.41 
Thus, working with a dietician is essential. Functional neu-
roimaging of individuals with PWS suggest this impairment 
of normal satiety response may be due to a hypothalamic 
dysfunction.78,79 Moreover, recent research suggests that the 
constant overeating and the persistent heightened interest in 
high-calorie foods may be related to abnormally increased 
neural activation in brain regions involved in appetite, food 
motivation, and reward.80 According to Holland and Wong,81 
individuals with PWS may not have the mental capacity to 
make decisions on eating. Thus, fundamental management 
of food-related issues involves 24-hour-a-day environmen-
tal control such as keeping all food under lock and key, 
disciplined supervision of food access, while instituting 
a low-calorie, well-balanced diet concordant with regular 
exercise.82,83 Interestingly, studies have found that BMI is 
significantly, negatively, related to aggressive behavior in 
both the deletion subtype and m-UPD subtypes while BMI 
was also significantly negatively related to symptoms of 
paranoia in the deletion subtype.42 In short, individuals with 
lower BMI are at an increased risk of problem behaviors 
for reasons that are not clear. One possibility is consistent 
with the limited strength model of self-control where self-
regulatory strength appears to be a limited resource that 
can be fatigued. Coping with stress may lead to a decreased 
ability to exert self-control.68 Thus, resisting a constant urge 
to eat food results in poorer performance on vigilance tasks 
in the non-PWS population, and results in a reduced ability 
to self-regulate one’s emotions and behaviors.84,85 Further 
research is needed to clarify these findings.42
Recent findings indicate that dietary treatment of reduced 
fat and modified carbohydrate meals starting at the 2nd year 
of life and continued until the age of 10 years was effective 
in avoiding excessive weight gain in patients with PWS com-
pared to individuals with PWS without this specific dietary 
intervention.86 On the other hand, findings indicated that 
patients on this strict dietary intervention had a significant 
decrease in height. Schmidt and colleagues’86 reason that 
individuals with PWS need a surplus of weight to achieve 
normal growth in height and thus, having a normal BMI, at 
a young age, would stunt the individuals’ final height. Carrel 
and colleagues87 found that treatment for growth hormone 
(GH) deficiency in PWS shows a dose-dependent effect on 
height, body composition, and resting energy expenditure.79 
It is possible a combination of the reduced fat and modified 
carbohydrate meals along with GH treatment may result in 
increased height along with normal BMI. This is the first 
long-term study with a follow-up report about the effective-
ness of early dietary intervention in children with PWS.
Some studies have reported effective intervention 
for problem behaviors in PWS, using applied behavior 
analysis (ABA) procedures. To date, research using ABA in 
PWS has been limited to single case or small sample size 
experiments. However, ABA procedures show promise as 
ABA is the primary method of treating aberrant behavior 
in individuals who have autism.88,89 Page and colleagues91 
eliminated food stealing in two children with PWS by using 
an ABA procedure called Differential Reinforcement of 
Other Behavior (DRO). In DRO, positive reinforcement is 
provided only when the target behavior is not displayed for 
a specified period of time. DRO has been one of the most 
used reinforcement procedures for the reduction of prob-
lem behavior in people who have intellectual disabilities.91 
In Page and colleagues’ study, the children were given 
tokens that could be exchanged for snacks when they did 
not exhibit food-stealing behavior during timed intervals.90 
A token-based program based on DRO was also effectively 
implemented in a separate study in hospital settings, a group 
home, and an apartment-living arrangement setting.92 Using 
another form of ABA, Maglieri and colleagues showed that 
food stealing in a 14-year-old girl with moderate mental 
retardation and PWS could be greatly reduced by combining 
verbal reprimands with a procedure to bring food stealing Neuropsychiatric Disease and Treatment 2010:6 112
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behavior under the control of stickers.93 Stickers were placed 
on certain containers filled with cookies and a reprimand 
was paired with taking food from containers with a sticker. 
In other words, the stickers were used as a way to label 
prohibited foods and the reprimand was used to discourage 
food taking. Maglieri and colleagues93 then placed a sticker 
on a refrigerator containing pudding cups to see if this skill 
could be generalized and this was equally effective in reduc-
ing covert food stealing. Because continuous supervision 
is difficult and individuals with PWS are skilled at covertly 
stealing food, this intervention may be effective for some 
individuals in reducing food-stealing behavior.
One of the most prevalent characteristics of PWS, regard-
less of genetic subtype, is skin picking, with the front of 
the legs and head being disproportionately targeted in this 
population.94 Dykens and Kasari administered the Child 
Behavior Checklist95 to parents of 43 children with PWS aged 
between 4 and 19 years and found that 95% of the children 
had problems with skin picking.96 Symons and colleagues94 
found that 82% of people surveyed with PWS in their sample 
(n = 62) showed some kind of skin-picking. Among children 
and adolescents, females are more inclined to skin pick than 
males.41 This gender difference is also seen in individuals 
with chronic skin picking (CSP) in the non-PWS popula-
tion.97 Skin picking in both populations may cause open 
sores to bleed and as a result, leave scarring, bruising, and 
lead to secondary infections. Cognitive behavioral interven-
tions such as habit-reversal training (HRT), which involves 
three primary components (awareness training, competing 
response training, and social support), have shown promise in 
treating CSP.98,99 A recent pilot study examining the efficacy 
of acceptance-enhanced behavior therapy, a combination of 
HRT with acceptance and commitment therapy (ACT), found 
this psychosocial intervention to be effective in reducing skin 
picking in CSP.100 Empirical investigation of these cognitive 
behavioral interventions has yet to be performed in the PWS 
population. In the short term, immediate treatment such as 
topical antibiotics and bandaging may decrease skin picking 
and the chances of infections.
While not as common as skin picking, approximately 
15% of adolescents and adults with PWS also display rec-
tal picking101 with an increased prevalence in those with 
UPD.11 Rectal picking has serious medical complications 
including blood loss, trauma to the anal sphincter, and peri-
rectal abscess.102 Treatment includes keeping the fingernails 
short, limiting the time spent in the bathroom to reduce 
opportunities for rectal picking, and behavior modification. 
While the few studies reporting ABA procedures in treating 
food-related behaviors show promise, behavioral treatment 
of self-injurious behavior among individuals with PWS has 
not been well documented.
Due to slightly different behavioral profiles present in 
the different genotypes; and because there are individual 
differences in the presence or absence of symptoms and the 
severity of symptoms, it is important to tailor assessments 
and interventions to each individual with PWS. Currently, 
little is known about the cause(s) of maladaptive behavior 
or other variables that are associated with the prevalence 
and severity of maladaptive behavior in individuals with 
PWS. While empirical studies of behavioral treatment are 
lacking, ABA interventions with individuals with PWS 
show promise and further evaluative research is warranted. 
However, before developing a behavior intervention plan, it 
is important to conduct a functional assessment to determine 
what factors are influencing the maladaptive behavior, so that 
a proper intervention or combination of interventions can be 
formulated. Information from a functional assessment helps 
yield more effective treatments than treatments without this 
assessment.103 Once a stable outcome has been achieved, 
gradually withdrawing procedures to support behavioral 
change is warranted as to increase independence in the 
individual with PWS.
Growth hormone
Those that suffer from severe growth hormone deficiency 
(GHD) show an impairment of growth hormone regulation 
due to abnormal hypothalamic functioning.104–107 In contrast 
to children with simple obesity, there is no enhancement 
of growth velocity despite onset of obesity in individuals 
with PWS. During adolescence, the growth rate declines 
due in part to inefficient testosterone and estrogen levels, 
resulting in the absence of the pubertal growth spurt.9,108 
Long-term GH therapy in patients with PWS has been shown 
to increase: height velocity and final adult height potential, 
lean body mass, muscle strength, and level of activity, and 
to decrease fat mass.109–114 As a result of decreased fat mass 
and increased lean body mass, GH treatment has also shown 
to improve pulmonary function in children with PWS.111,115 
While the benefits of GH therapy are well documented, the 
behavioral and cognitive implications of GH treatment are 
not as unequivocal in the PWS population. Those that suffer 
from severe GHD from other etiologies suffer from a negative 
quality of life and possibly psychological symptoms such as 
poor memory, social withdrawal, and depression.116 However, 
these problems improve with GH therapy.116 GH therapy in 
other populations is known to increase energy levels, increase Neuropsychiatric Disease and Treatment 2010:6 113
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sexual function, and improve weight management, all effects 
that have behavioral and possibly cognitive implications.
Collectively, studies have generally shown promise 
regarding the effects of GH therapy on behavior, cogni-
tion, and quality of life in persons with PWS. While earlier 
studies117,118 have found beneficial effects on intellectual 
speed and flexibility, Haqq and colleagues111 found no influ-
ence of GH intervention on cognitive function in children 
with PWS. However, in a pilot study evaluating behavior 
in young adults with PWS at baseline, during and after GH 
treatment, Hoybye, Thoren, and Bohm reported beneficial 
effects on mental speed, flexibility, and motor performance 
after 6 to 18 months of GH treatment and a decrease in overall 
functioning back to baseline levels when GH treatment was 
discontinued at either 3 or 6 months after cessation.119 Recent 
studies have also suggested that early GH therapy in infants 
with PWS improves cognition. In a randomized, controlled 
study, Myers and colleagues120 randomized 25 infants and 
toddlers with PWS, ages 4–37 months to either 2 years of 
GH therapy or 1 year of observation without GH therapy then 
1 year of GH treatment. The 2-year GH-treated PWS group 
had increased rate of language and cognitive development 
along with increased head circumference. Consistent with 
these findings, Festen and colleagues121 also found improve-
ment in mental development after 1 year of treatment in a 
randomized, controlled trial in infants and toddlers aged 
between 6 months and 3 years. Whether these cognitive 
improvements are just short-term benefits or are due to long-
term effects such as changes in underlying brain structure is 
unknown. Cognitive improvements as an indirect result of 
improved muscle function allowing children to better able 
explore their surroundings cannot be ruled out. Regardless of 
whether these benefits are direct changes to underlying brain 
structures or as a function of indirect results, these findings 
are promising. Employing longitudinal designs to examine 
sustained benefits are warranted given these findings.
Behavioral changes have also been noted as a result of GH 
treatment in children with PWS. Eiholzer and colleagues106 
found, through parent reporting, that GH treatment increased 
alertness and enjoyment in physical activity in children with 
PWS. Similarly, Whitman and colleagues122 found a signifi-
cant reduction of depressive symptoms from baseline to time 
1 (12 months) and retained at 24 months among those treated 
with GH. However, for children aged 11 years and younger, 
a significant increase in attention-deficit/hyperactivity 
symptoms was observed. Haqq and colleagues111 also 
found a significant increase in the hyperactivity scale on the 
Behavior Assessment System for Children and subjective 
parent reports also reported increased alertness in GH treated 
individuals with PWS.123
GH therapy is currently considered to be a standard ele-
ment of the comprehensive care children with PWS receive.124 
A recent multicenter study found that along with improving 
a number of physical characteristics previously mentioned 
before, no adverse effects of long-term GH treatment in 
a large group of prepubertal children was found.125 Since 
July 2000, the United States Food and Drug Administration 
(FDA) approved GH for children with PWS regardless of 
the presence of growth hormone deficiency. However, in 
Tauber and colleagues’ review of 64 cases of death in chil-
dren with PWS, the authors suggest that the first 9 months 
of GH therapy has a higher risk period of death compared to 
later months.6 As a result, increased vigilance may be war-
ranted during early stages of such treatment. For those with 
pre-existing conditions such as URI, tonsilor/adenoid hyper-
trophy, severe obesity, and high insulin-like growth factor I 
(IGF-I), close monitoring to worsening of these symptoms 
is necessary, especially in individuals undergoing GH treat-
ment. Despite this, convincing evidence that children treated 
with GH have a higher mortality rate than untreated patients 
or that GH therapy is directly involved in patients’ deaths is 
not present.6,124 On the other hand, GH treatment may even 
improve sleep-disordered breathing, which includes sleep 
apnea, in individuals with PWS.111,126,127
Pharmacological and surgical 
treatment
Treatment with numerous psychotropic medications such 
as antidepressants, antipsychotics, appetite suppressants, 
and others have shown limited effectiveness in controlling 
hyperphagia and nonfood-related issues. There is no spe-
cific pharmacologic treatment for PWS specific behavioral 
disturbances. Hyperphagia in PWS is related to decreased 
satiation rather than increased hunger and as a result, appetite 
suppression medications have not been effective.76 Restric-
tive bariatric surgery has also not been effective in reducing 
hyperphagia or long-term weight reduction and has been asso-
ciated with increased morbidity and mortality.128 Serotonin 
agonists (SSRIs) have been the most successful in reducing 
temper outbursts and improving compulsivity in PWS.129,130 
Serotonin imbalance has been linked to repetitive behavior, 
obsessive and compulsive behavior, depression, anxiety, 
and self-injurious behavior in the non-PWS population.131 
Holland and colleagues,23 through factor-analysis, found that 
skin-picking and mood swings were related and thus could 
have a common underlying etiologic mechanism. The use of Neuropsychiatric Disease and Treatment 2010:6 114
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fluoxetine in an adolescent with PWS has been reported in a 
case study, with improvement in bodyweight and decreased 
compulsive behavior.129 Hellings and Warnock reported that 
treatment with fluoxetine reduced skin picking behavior.130 
In an 8-week open-label study primarily examining Topira-
mate as an appetite-regulating medication, Shapira and col-
leagues unexpectedly found that Topiramate did not reduce 
food-related behaviors but did reduce skin picking.132 These 
reports are in agreement with previous studies133–135 using 
SSRIs. On the other hand, Kohn and colleagues136 reported 
an aggravation in food-related symptoms and a consequent 
weight gain in an adolescent treated with fluoxetine and 
fluvoxamine. Studies to date have been small; controlled 
and randomized studies have yet to be performed. Future 
studies should explore the differential treatment effects of 
individuals with PWS based on subtyping and the potential 
efficacy of combined psychotherapy and pharmacology to 
improve outcome.
Given the prevalence of psychosis in PWS, families and 
caregivers should be vigilant for symptoms of this disorder 
as individuals age. It is particularly important to be aware 
that while psychosis is common in PWS, the prevalence 
rates are significantly higher in adults with UPD or imprint-
ing defects.16,18,39 Because individuals with PWS have a 
lower tolerance for change or hardships in the immediate 
environment, it is important to assess the precipitating and 
perpetuating factors that may be causing a change in mood 
before an intervention is implemented. Currently, there are 
few research studies published on the efficacy and use of 
psychotropic medications in treating psychiatric illness in 
the PWS population. As a result, psychiatric illness in PWS 
is treated in a standard manner by identifying behaviors and 
symptoms for a psychiatric disorder and treating them as 
such, whether it is through cognitive behavioral strategies 
or through medication.
Conclusion
Beneficial effects on behavior and cognition have been shown 
thus far in small controlled studies and parent reports. Larger 
cohort studies and replication of results with parallel mea-
surements would substantiate findings. To date, due to the 
rarity of the disorder, larger and more systematic studies on 
the management and treatment of behavior have been dif-
ficult to conduct. The benefits of GH therapy have shown to 
improve somatic symptoms both in the short and long-term 
in individuals with PWS. While aggravation of pre-existing 
conditions due to GH therapy have been found in some 
individuals; and should be closely monitored, the benefits 
of GH treatment are substantial as it not only improves 
physical characteristics and psychomotor development, but 
also has psychological and behavioral benefits with no known 
substantiated side effects.
On the other hand, it is important to remind parents and 
caregivers that GH treatment is not a panacea and long-term 
adaptation improvements are most effective with sustained 
behavioral intervention strategies that allow individuals with 
PWS to actively deal with their problems. Before developing 
a behavior intervention plan, a functional assessment should 
be conducted to determine what factors are influencing the 
maladaptive behavior so that a proper intervention or com-
bination of interventions can be formulated. Food-related 
issues are the most debilitating and thus, management of 
food-related issues should be addressed first. This includes 
restricting access to food while instituting a low-calorie and 
well-balanced diet in concordance with regular exercise. 
ABA interventions with individuals with PWS show promise 
in managing and increasing independence in individuals with 
PWS. Not only is increased independency directly beneficial 
to the individual with PWS, but it also relieves some of the 
burden off of the family and/or caregivers. Pharmacological 
treatment, GH treatment, and surgery have yet to show 
positive effects in treating hyperphagia although anecdotal 
reports from parents and caretakers indicate the possibility 
that food intake may be easier to control with an individual 
on GH therapy.
Studies on the effectiveness of pharmacological medica-
tion in controlling PWS specific behaviors may have benefits 
to the patient, although some side effects have been reported. 
Furthermore, the benefits have been shown in uncontrolled 
studies with small sample sizes. Thus, pharmacological treat-
ment should be used only with caution and in combination 
with psychiatric support and behavioral management. One 
of the most prevalent characteristics of PWS is skin pick-
ing. In the short term, immediate treatment such as topical 
antibiotics and bandaging may decrease skin picking and the 
chances of infections. In the long-term, acceptance-enhanced 
behavior therapy may be an effective method of decreasing 
self-injury. However, behavioral treatment of self-injurious 
behavior among individuals with PWS has not been well 
documented.
While speech and language skills differ greatly among 
individuals with PWS, early assessment and intervention 
by a speech-language pathologist is critical for develop-
ing future communication skills especially for those most 
severely affected. Early intervention focusing on improving 
oral motor skills can improve feeding in infancy. Later on, Neuropsychiatric Disease and Treatment 2010:6 115
Clinical management of PwS Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
intervention should not only emphasize improvements in 
articulation and language, but also pragmatics, concurrently 
with managing behavioral problems, because maladaptive 
behaviors hinder satisfactory pragmatic language ability. 
Because PWS is a multisystem disorder, a multidisciplinary 
approach to treatment is recommended to achieve the best 
possible outcome for each individual. Primary care physi-
cians should have active dialogue with the various special-
ists involved in management of this syndrome throughout 
the lifespan.
Disclosures
The authors report no conflicts of interest in this work.
References
  1.  Whittington JE, Holland AJ, Webb T, Butler J, Clarke D, Boer H. Popu-
lation prevalence and estimated birth incidence and mortality rate for 
people with Prader-Willi syndrome in one UK Health Region. Journal 
of Medical Genetics. 2001;38(11):792–298.
  2.  Holm V , Cassidy S, Butler M, et al. Prader-Willi syndrome: Consensus 
diagnostic criteria. Pediatrics. 1993;91:398–402.
  3.  Maggio MC, Corsello M, Piccione M, Prio E, Giuffre M, Liotta A. 
Neonatal presentation of Prader-Willi syndrome. Personal Records. 
Minerva Pediatrica. 2007;59(6):817–823.
  4.  Curfs LM, Verhulst FC, Fryns JP. Behavioural and emotional problems 
in youngsters with Prader-Willi syndrome. Genetic Counseling. 
1991;2:33–41.
  5.  Lewis BA, Freebairn L, Heeger S, Cassidy SB. Speech and language 
skills of individuals with Prader-Willi Syndrome. American Journal of 
Speech-Language Pathology. 2002;11:285–294.
  6  Tauber M, Diene G, Molinas C, Hebert M. Review of 64 cases of death 
in children with Prader-Willi syndrome (PWS). American Journal of 
Medical Genetics Part A. 2008;146(7):881–887.
  7.  Einfeld SL, Kavanagh SJ, Smith A, Evans EJ, Tonge BJ, Taffe J. Mortality 
in Prader-Willi syndrome. American Journal of Mental Retardation. 
2006;111(3):193–198.
  8.  Bittel DC, Butler MG. Prader-Willi syndrome: clinical genetics, 
cytogenetics and molecular biology. Expert Reviews in Molecular 
Medicine. 2005;7:1–20.
  9.  Butler MG, Meaney FJ. Standards for selected anthropometric measure-
ments in Prader-Willi syndrome. Pediatrics. 1991;88:853–860.
10.  Toth-Fejel S, Olson S, Gunter K, et al. The impact of imprinting: 
Prader-Willi syndrome resulting from chromosome translocation, 
recombination, and nondisjunction. American Journal of Human 
Genetics. 1996;58(5):1008–1016.
11.  Dykens EM, Roof E. Behavior in Prader-Willi syndrome: relationship 
to genetic subtypes and age. The Journal of Child Psychology and 
Psychiatry. 2008;49(9):1001–1008.
12.  ASHG/ACMG report. Diagnostic testing for Prader-Willi and 
Angelman syndromes: Report of the ASHG/CMG Test and Technology 
Transfer Committee. American Journal of Human Genetics. 1996;58: 
1085–1089.
13.  Cassidy SB, Schwartz S. Prader-Willi and Angelman syndromes. 
Disorders of genomic imprinting. Medicine (Baltimore). 1998;77(2): 
140–151.
14.  Gunay-Aygun M, Schwartz C, O’Riordan MA, Cassidy SB. The 
changing purpose of Prader-Willi syndrome clinical diagnostic criteria 
and proposed revised criteria. Pediatrics. 2001;108:E92.
15.  Monaghan KG, Wiktor A, Van Dyke DL. Diagnostic testing for 
Prader-Willi syndrome and Angelman syndrome: a cost comparison. 
Genetics in Medicine. 2002;4(5):448–450.
16.  Boer H, Holland AJ, Whittington JE, Butler J, Webb T, Clarke 
D. Psychotic illness in people with Prader-Willi syndrome due 
to chromosome 15 maternal uniparental disomy. The Lancet. 
2002;359:135–136.
17.  Wigren M, Hansen S. ADHD symptoms and insistence on sameness 
in Prader-Willi syndrome. Journal of Intellectual Disability Research. 
2005;49:449–456.
18.  Verhoeven WM, Tuinier S, Curfs LM. Prader-Willi syndrome: the 
psychopathological phenotype in uniparental disomy. Journal of 
Medical Genetics. 2003;40(10):e112.
19.  Dykens EM, Cassidy SB, King BH. Maladaptive behavior differences 
in Prader-Willi syndrome due to paternal deletion versus maternal 
uniparental disomy. American Journal of Mental Retardation. 
1999;104:67–77.
20.  Whittington JE, Holland AJ, Webb T, Butler J, Clarke D, Boer H. 
Cognitive abilities and genotype in a population-based sample of people 
with Prader-Willi syndrome. Journal of Intellectual Disability Research. 
2004;48:172–188.
21.  Roof E, Stone W, MacLean W, Feurer ID, Thompson T, Butler MG. 
Intellectual characteristics of Prader-Willi syndrome: comparison 
of genetic subtypes. Journal of Intellectual Disability Research. 
2000;44(Pt 1):25–30.
22.  Beardsmore A, Dorman T, Cooper SA, Webb T. Affective psychosis 
and Prader-Willi syndrome. Journal of Intellectual Disability Research. 
1998;42(6):463–471.
23.  Holland AJ, Whittington JE, Butler J, Webb T, Boer H, Clarke D. 
Behavioral phenotypes associated with specific genetic disorders: 
evidence from population-based study of people with Prader-Willi 
syndrome. Psychological Medicine. 2003;33:141–153.
24.  Dykens EM, Cassidy SB. Prader-Willi syndrome: Genetic, behavioral, 
and treatment issues. Child and Adolescent Psychiatric Clinics of North 
America. 1996;5:913–927.
25.  Einfeld SL, Smith A, Durvasula S, Florio T, Tonge BJ. Behavior and 
emotional disturbance in Prader-Willi syndrome. American Journal of 
Medical Genetics. 1999;82:123–127.
26.  State MW, Dykens EM, Rosner B, Martin A, King BH. Obsessive-
compulsive symptoms in Prader-Willi and “Prader-Willi-like” patients. 
Journal of American Academy of Child Adolescent Psychiatry. 
1999;38:329–334.
27.  Dimitropoulos A, Feurer I, Butler M, Thompson T. Emergence of 
compulsive behavior and tantrums in children with Prader-Willi syn-
drome. American Journal on Mental Retardation. 2001;106(1):39–51.
28.  Dykens EM, Leckman JF, Cassidy SB. Obsessions and compulsions in 
Prader-Willi syndrome. Journal of Child Psychology and Psychiatry. 
1996;37(8):995–1002.
29.  Stein DJ, Keating J, Zar HJ, E H. A survey of the phenomenology and 
pharmacotherapy of compulsive and impulsive-aggressive symptoms 
in Prader-Willi syndrome. The Journal of Neuropsychiatry and Clinical 
Neurosciences. 1994;6:23–29.
30.  Dimitropoulos A, Blackford J, Walden T, Thompson T. Com-
pulsive behavior in Prader-Willi syndrome: Examining sever-
ity in early childhood. Research in Developmental Disabilities. 
2006;27:190–202.
31.  Dimitropoulos A, Schultz RT. Autistic-like Symptomatology in 
Prader-Willi Syndrome: A Review of Recent Findings. Current 
Psychiatry Reports. 2007;9:159–164.
32.  Vitiello B, Spreat S, Behar D. Obsessive-compulsive disorder in 
mentally retarded patients. Journal of Nervous and Mental Disease. 
1989;177(4):232–236.
33.  Greaves N, Prince E, Evans DW, Charman T. Repetitive and ritualistic 
behaviour in children with Prader-Willi syndrome and children with 
autism. Journal of Intellectual Disability Research. 2006;50(Pt 
2):92–100.
34.  Descheemaeker MJ, Govers V, Vermeulen P, Fryns JP. Pervasive 
developmental disorders in Prader-Willi syndrome: The Leuven 
experience in 59 subjects and controls. American Journal of Medical 
Genetics A. 2006;140(11):1136–1142.Neuropsychiatric Disease and Treatment 2010:6 116
Ho and Dimitropoulos Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
35.  Veltman MW, Craig EE, Bolton PF. Autism spectrum disorders 
in Prader-Willi and Angelman syndromes: a systematic review. 
Psychiatric Genetics. 2005;15(4):243–254.
36.  Shroer RJ, Phelan MC, Michaelis RC, et al. Autism and maternally 
derived aberrations of chromosome 15q. American Journal of Medical 
Genetics. 1998;76(4):327–336.
37.  Cook EH Jr, Courchesne RY, Cox NJ, et al. Linkage-disequilibrium 
mapping of autistic disorder, with 15q11–13 markers. American Journal 
of Medical Genetics. 1998;62(5):1077–1083.
38.  Webb T, Whittington JE, Clarke D, Boer H, Butler J, Holland A. A study 
of the influence of different genotypes on the physical and behavioral 
phenotypes of children and adults ascertained clinically as having PWS. 
Clinical Genetics. 2002;62:273–281.
39.  Vogels A, Matthigs G, Legius E, Devriendt K, Fryns JP. Chromosome 
15 maternal uniparental disomy and psychosis in Prader-Willi 
syndrome. Journal of Medical Genetics. 2003;40:72–73.
40.  Hiraiwa R, Maegaki Y, Oka A, Ohno K. Behavioral and psychiatric 
disorders in Prader-Willi syndrome: A population study in Japan. Brain 
and Development. 2007;29(9):535–542.
41.  Dykens EM. Maladaptive and compulsive behavior in Prader-Willi 
syndrome: New insights from older adults. American Journal of Mental 
Retardation. 2004;109(2):142–153.
42.  Hartley SL, Maclean WE Jr, Butler MG, Zarcone J, Thompson T. 
Maladaptive behaviors and risk factors among the genetic subtypes 
of Prader-Willi syndrome. American Journal of Medical Genetics A. 
2005;136(2):140–145.
43.  Butler MG, Bittel DC, Kibiryeva N, Talebizadeh Z, Thompson T. 
Behavioral differences among subjects with Prader-Willi syndrome and 
type I or type II deletion and maternal disomy. American Academy of 
Pediatrics. 2004;113:565–573.
44.  Zarcone J, Napolitano D, Peterson C, et al. The relationship between 
compulsive behavior and academic achievement across three genetic 
subtypes of Prader-Willi syndrome. Journal of Intellectual Disabilities 
Research. 2007;51:478–487.
45.  Milner KM, Craig EE, Thompson RJ, et al. Prader-Willi syndrome: 
Intellectual disabilities and behavioral features by genetic 
subtype. Journal of Child Psychology and Psychiatry. 2005;46: 
1089–1096.
46.  Dykens EM, Hodapp RM, Walsh K, Nash L. Profiles, correlates and 
trajectories of intelligence in individuals with Prader-Willi syndrome. 
Journal of American Academy of Child and Adolescent Psychiatry. 
1992;31:1125–1130.
47.  Curfs LM, Fryns JP. Prader-Willi Syndrome: a review with special 
attention to the cognitive and behavioral profile. Birth Defects Original 
Article Series. 1992;28:99–104.
48.  Gross-Tsur V , Landau YE, Benarroch F, Wertman-Elad R, Shalev RS. 
Cognition, attention, and behavior in Prader-Willi syndrome. Journal 
of Child Neurology. 2001;16(4):288–290.
49.  Bertella L, Girelli L, Grugni G, Marchi S, Molinar E, Semenza C. 
Mathematical skills in Prader-Willi Syndrome. Journal of Intellectual 
Disability Research. 2005;49:159–169.
50.  Walley RM, Donaldson MDC. An investigation of executive function 
abilities in adults with Prader-Willi syndrome. Journal of Intellectual 
Disability Research. 2005;49:613–625.
51.  Cassidy SB, Forsythe M, Heeger S, et al. Comparison of phenotype 
between patients with Prader-Willi syndrome due to deletion 15q 
and uniparental disomy 15. American Journal of Medical Genetics. 
1997;68:433–440.
52.  Conners FA, Rosenquist CJ, Atwell JA, Klinger LG. Cognitive strengths 
and weaknesses associated with Prader-Willi syndrome. Education 
and Training in Mental Retardation and Developmental Disabilities. 
2000;35:442–449.
53.  Curfs LM, Wiegers AM, Sommers JR, Borghgraef M, Fryns JP. 
Strengths and weaknesses in cognitive profile of youngsters with 
Prader-Willi syndrome. Clinical Genetics. 1991;40(6):430–434.
54.  Koenig K, Klin A, Schultz R. Deficits in social attribution ability 
in Prader-Willi Syndrome. Journal of Autism and Developmental 
Disorders. 2004;34:573–582.
55.  Gabel S, Tarter RE, Gavaler J, Golden W, Hegedus AM, Mair B. 
Neuropsychological capacity of Prader-Willi children: General and 
specific aspects of impairment. Applied Research in Mental Retardation. 
1986;7:459–466.
56.  Verdine BN, Troseth GL, Hodapp RM, Dykens EM. Strategies and 
correlates of jigsaw puzzle and visuospatial performance by persons 
with Prader-Willi Syndrome. American Journal on Mental Retardation. 
2008;113(5):343–355.
57.  Liben LS, Susman EJ, Finkelstein JW, et al. The effects of sex steroids 
on spatial performance: A review and an experimental clinical investi-
gation. Developmental Psychology. 2002;38:236–253.
58.  Fox R, Yang GS, Feurer ID, Butler MG, Thompson T. Kinetic form 
discrimination in Prader-Willi syndrome. Journal of Intellectual 
Disability Research. 2001;45:317–325.
59.  Woodcock KA, Humphreys GW, Oliver C. Dorsal and ventral stream 
mediated visual processing in genetic subtypes of Prader-Willi 
syndrome. Neuropsychologia. 2009;47:2367–2373.
60.  Akefeldt A, Akefeldt B, Gilberg C. Voice, speech and language 
characteristics of children with Prader-Willi syndrome. Journal of 
Intellectual Disability Research. 1997;41:302–311.
61.  Kleppe SA, Katayama KM, Shipley KG, Foushee DR. The speech 
and language characteristics of children with Prader-Willi syndrome. 
Journal of Speech and Hearing Disorders. 1990;55:300–309.
62.  Van Borsel J, Defloor T, Curfs LM. Expressive language in persons 
with Prader-Willi syndrome. Genetic Counseling. 2007;18(1):17–28.
63.  Guralnick MJ, Hammond MA, Neville B, Connor RT. The relationship 
between sources and functions of social support and dimensions of 
child- and parent-related stress. Journal of Intellectual Disability 
Research. 2008;52(12):1138–1154.
64.  Ha JH, Hong J, Seltzer MM, Greenberg JS. Age and gender differences 
in the well-being of midlife and aging parents with children with mental 
health or developmental problems: Report of a national study. Journal 
of Health and Social Behavior. 2008;49(3):301–316.
65.  Steinhaussen HC, Eiholzer U, Hauffa BP, Malin Z. Behavioural and 
emotional disturbances in people with Prader-Willi syndrome. Journal 
of Intellectual Disability Research. 2004;48(1):47–52.
66.  Dykens EM, Hodapp RM, Walsh K, Nash LJ. Adaptive and maladaptive 
behavior in Prader-Willi syndrome. Journal of the American Academy 
of Child and Adolescent Psychiatry. 1992;31:1131–1135.
67.  Cipani E, Spooner F. Treating problem behaviors maintained by nega-
tive reinforcement. Research in Developmental Disabilities. 1997;18: 
329–342.
68.  Muraven M, Baumeister R. Self-regulation and depletion of limited 
resources: does self-control resemble a muscle? Psychological Bulletin. 
2000;126(2):247–259.
69.  Carstensen LL. The influence of a sense of time on human development. 
Science. 2006;312(5782):1913–1915.
70.  Dimitropoulos A, Ho AY, Klaiman C, Koenig K, Schultz RT. 
A comparison of behavioral and emotional characteristics in children 
with autism, Prader-Willi Syndrome, and Williams Syndrome. Jour-
nal of Mental Health Research in Intellectual Disabilities. 2009;2: 
220–243.
71.  Zipf WB, Berntson GG. Characteristics of abnormal food-intake 
patterns in children with Prader-Willi syndrome and study of effects 
of naloxone. American Journal of Clinical Nutrition. 1987;26(2): 
277–281.
72.  Caldwell ML, Taylor RL. A clinical note on food preference of 
individuals with Prader-Willi syndrome: the need for empirical research. 
Journal of Mental Deficiency Research. 1983;27(Pt 1):45–49.
73.  Glover D, Maltzman I, Williams C. Food preferences among individuals 
with and without Prader-Willi syndrome. American Journal of Mental 
Retardation. 1996;101(2):195–205.
74.  Joseph B, Egli M, Koppekin A, Thompson T. Food choice in people 
with Prader-Willi syndrome: Quantity and relative preference. American 
Journal on Mental Retardation. 2002;107(2):128–135.
75.  Dykens EM. Contaminated and unusual food combinations: what 
do people with Prader-Willi syndrome choose? Mental Retardation. 
2000;38(2):163–171.Neuropsychiatric Disease and Treatment 2010:6 117
Clinical management of PwS Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
76.  Lindgren AC, Barkeling B, Hagg A, Ritzen EM, Marcus C, Rossner S. 
Eating behavior in Prader-Willi syndrome, normal weight, and obese 
control groups. Journal of Pediatrics. 2000;137(1):50–55.
77.  Holland AJ, Treasure J, Coskeran P, Dallow J, Milton N, Hillhouse E. 
Measurement of excessive appetite and metabolic changes in Prader-
Willi syndrome. International Journal of Obesity and Related Metabolic 
Disorders. 1993;17(9):527–532.
  78.  Shapira NA, Lessig MC, He AG, James GA, Driscoll DJ, Liu Y. 
Satiety dysfunction in Prader-Willi syndrome demonstrated by fMRI. 
Journal of Neurology, Neurosurgery, and Psychiatry. 2005;76(2): 
260–262.
  79.  Holland A, Whittington J, Hinton E. The paradox of Prader-Willi 
syndrome: a genetic model of starvation. Lancet. 2003;362(9388): 
989–991.
  80.  Dimitropoulos A, Schultz RT. Food-related Neural Circuitry 
in Prader-Willi Syndrome: Response to high- versus low-calorie 
foods. Journal of Autism and Developmental Disorders. 2008;38(9): 
1642–1653.
  81.  Holland AJ, Wong J. Genetically determined obesity in Prader-Willi 
syndrome: the ethics and legality of treatment. Journal of Medical 
Ethics. 1999;25:230–236.
  82.  Hoffmann C, Aultman D, Pipes P. A nutrition survey of and recommenda-
tions for individuals with Prader-Willi syndrome who live in group homes. 
Journal of the American Dietetic Association. 1992;92(7):823–833.
  83.  Stadler DD. Nutritional Management of Prader-Willi Syndrome. 2 ed; 
1995.
  84.  Green MW, Rogers PJ. Impaired cognitive functioning during spontane-
ous dieting. Psychological Medicine. 1995;25:1003–1010.
  85.  Green MW, Rogers PJ, Elliman NA, Gatenby SJ. Impairment of cognitive 
performance associated with dieting and high levels of dietary restraint. 
Physiology and Behavior. 1994;55:447–452.
  86.  Schmidt H, Pozza SB, Bonfig W, Schwarz HP, Dokoupil K. Successful 
early dietary intervention avoids obesity in patients with Prader-Willi 
syndrome: a ten year follow-up. Journal of Pediatric Endocrinology 
and Metabolism. 2008;21(7):651–655.
  87.  Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term 
GH therapy in Prader-Willi syndrome: a 4 year study. Journal of Clinical 
Endocrinology and Metabolism. 2002;87(4):1581–1585.
  88.  Baer D, Wolf M, Risley R. Some still-current dimensions of 
applied behavior analysis. Journal of Applied Behavior Analysis. 
1987;20:313–327.
  89.  Granpeesheh D, Tarbox J, Dixon DR. Applied behavior analytic inter-
ventions for children with autism: a description and review of treatment 
research. Annals of Clinical Psychiatry: Official Journal of the American 
Academy of clinical Psychiatrists. 2009;21(3):162–173.
90.  Page TJ, Finney JW, Parrish JM, Iwata BA. Assessment and reduction 
of food stealing in Prader-Willi children. Applied Research in Mental 
Retardation. 1983;4:219–228.
  91.  Lennox DB, Miltenberger RG, Spengler P, Erfanian N. Decelerative 
treatment practices with persons who have mental retardation: A review 
of five years of the literature. American Journal on Mental Retardation. 
1988;92:492–501.
  92.  Page TJ, Stanley AE, Richman GS, Deal RM, Iwata BA. Reduction of 
food theft and long-term maintenance of weight loss in a Prader-Willi 
adult. Journal of Behavior Therapy and Experimental Psychiatry. 
1983;14(3):261–268.
  93.  Maglieri KA, DeLeon IG, Rodriquez-Catter V , Sevin BM. Treatment 
of covert food stealing in an individual with Prader-Willi syndrome. 
Journal of Applied Behavior Analysis. 2000;33:615–618.
  94.  Symons FJ, Butler MG, Sanders MD, Feurer ID, Thompson T. Self-
injurious behavior and Prader-Willi syndrome: behavioral forms and 
body locations. American Journal of Mental Retardation. 1999;104(3): 
260–269.
  95.  Achenbach T. Manual for the Child Behavior Checklist. Burlington, 
VT; 1991.
  96.  Dykens E, Kasari C. Maladaptive behavior in Prader-Willi syndrome, 
Down syndrome, and nonspecific mental retardation. American Journal 
of Mental Retardation. 1997;102:228–237.
  97.  Bloch MR, Elliot M, Thompson H, Koran LM. Fluoxetine in pathologic 
skin-picking. Psychosomatics. 2001;42;314–319.
  98.  Teng EJ, Woods DW, MP T. Habit reversal as a treatment for 
chronic skin picking: A pilot investigation. Behavior Modification. 
2006;30:411–422.
  99.  Twohig MP, Woods DW. Habit reversal as a treatment for chronic skin 
picking in typically developing adult male siblings. Journal of Applied 
Behavior Analysis. 2001;34:217–220.
100.  Flessner  CA,  Busch  AM,  Heideman  PW,  Woods  DW. 
Acceptance-enhanced behavior therapy (AEBT) for trichotillomania 
and chronic skin picking: exploring the effects of component sequenc-
ing. Behavior Modification. 2008;32(5):579–594.
101.  Hanchett J. Skin picking and other forms of self-trauma in Prader-Willi 
syndrome. Gathered View. 1994:37.
102.  Stokes JV, Luiselli JK. Applied behavior analysis assessment and 
intervention for health: threatening self-injury (rectal picking) 
in an adult with Prader-Willi syndrome. Clinical Case Studies. 
2009;8(1):38–47.
103.  Campbell J. Efficacy of behavioral interventions for reducing 
problem behavior in persons with autism: a quantitative synthesis 
of single-subject research. Research in Developmental Disabilities. 
2003;24:120–138.
104.  Brambilla P, Bosio L, Manzoni P, Pietrobelli A, Beccaria L, 
Chiumello G. Peculiar body composition in patients with Prader-Labhart-
Willi syndrome. American Journal of Clinical Nutrition. 1997;65: 
1369–1374.
105. Eiholzer U, Bachmann S, l’Allemand D. Is there growth hormone 
deficiency in Prader-Willi Syndrome: Six arguments to support 
the presence of hypothalamic growth hormone deficiency in 
Prader-Willi syndrome. Hormone Research. 2000;53(Supplement 
3):44–52.
106.  Eiholzer U, Giosin R, Weinmann C, et al. Treatment with human growth 
hormone in patients with Prader-Labhart-Willi syndrome reduces body 
fat and increases muscle mass and physical performance. European 
Journal of Pediatrics. 1998;157(5):368–377.
107.  Costeff H, Holm AV , Ruvalcaba R, J S. Growth hormone secretion 
in Prader-Willi syndrome. Acta Paediatrica Scandinavica. 
1990;79(11):1059–1062.
108.  Nagai T, Matsuo N, Kayanuma Y, et al. Standard growth curves for 
Japanese patients with Prader-Willi syndrome. American Journal of 
Medical Genetics. 2000;95:130–134.
109.  Angulo MA, Castro-Magana M, Lamerson M, Arguello R, Accacha S, 
Khan A. Final adult height in children with Prader-Willi syndrome with 
and without human growth hormone treatment. American Journal of 
Medical Genetics. 2007;143:1456–1461.
110.  Carrel AL, Meyers SE, Whitman BY, Allen DB. Sustained benefits 
of growth hormone on body composition, fat utilization, physical 
strength, and agility, and growth in Prader-Willi syndrome are dose-
dependent. Journal of Pediatric Endocrinology and Metabolism. 
2001;14(8):1097–1105.
111.  Haqq AM, Stadler DD, Jackson RH, Rosenfeld RG, Purnell JQ, 
LaFranchi SH. Effects of growth hormone on pulmonary function, 
sleep quality, behavior, cognition, growth velocity, body composi-
tion, and resting energy expenditure in Prader-Willi syndrome. 
Journal of Clinical Endocrinology Metabolism. 2003;88(5): 
2206–2212.
112.  Hoybye C. Five-years growth hormone (GH) treatment in adults with 
Prader-Willi syndrome. Acta Paediatrica. 2007;96:410–413.
113.  Lindgren AC, Ritzen EM. Five years of growth hormone treatment 
in children with Prader-Willi syndrome. Swedish National Growth 
Hormone Advisory Group. Acta Paediatrica Supplementum. 
1999;88(433):109–111.
114.  Mogul HR, Lee PDK, Whitman BY, et al. Growth hormone treatment 
of adults with Prader-Willi syndrome and growth hormone deficiency 
improves lean body mass, fractional body fat, and serum triiodothy-
ronine without glucose impairment: results from the United States 
multicenter trial. Journal of Clinical Endocrinology Metabolism. 
2008;93(4):1238–1245.Neuropsychiatric Disease and Treatment 2010:6
Neuropsychiatric Disease and Treatment
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing on 
concise rapid reporting of clinical or pre-clinical studies on a range of 
neuropsychiatric and neurological disorders. This journal is indexed on 
PubMed Central, the ‘PsycINFO’ database and CAS, and is the official 
journal of The International Neuropsychiatric Association (INA). The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
118
Ho and Dimitropoulos Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
115.  Lindgren AC, Hellstrom LG, Ritzen EM, Milerad J. Growth hormone 
treatment increases CO(2) response, ventilation and central inspiratory 
drive in children with Prader-Willi syndrome. European Journal of 
Pediatrics. 1999;158(11):936–940.
116.  Gilchrist FJ, Murray RD, Shalet SM. The effect of long-term untreated 
growth hormone deficiency (GHD) and 9 years of GH replacement 
on the quality of life (QoL) of GH-deficient adults. Clinical 
Endocrinology. 2002;57:363–370.
117.  Mard G, Lundin K, Borg G, Jonsson B, Lindberg A. Growth hormone 
replacement therapy in adult hypopituitary patients with growth hormone 
deficiency: combined data from 12 European placebo-controlled clinical 
trials. Endocrinology and Metabolism. 1994;I(Suppl A):43–49.
118.  Murray RD, Skillicorn CJ, Howell SJ, et al. Influences on quality of 
life in GH deficient adults and their effect on response to treatment. 
Clinical Endocrinology (Oxf ). 1999;51(5):565–573.
119.  Hoybye C, Thoren M, Bowhm B. Cognitive, emotional, physical, 
and social effects of growth hormone treatment in adults with 
Prader-Willi syndrome. Journal of Intellectual Disability Research. 
2005;49(4):245–252.
120.  Meyers SE, Whitman BY, Carrel AL, Moerchen V , Bekx MT, Allen DB. 
Two years of growth hormone therapy in young children with Prader-
Willi syndrome: physical and neurodevelopmental benefits. American 
Journal of Medical Genetics Part A. 2006;143A:443–448.
121.  Festen DAM, Wevers M, Lindgren AC, et al. Mental and motor 
development before and during growth hormone treatment in infants 
and toddlers with Prader-Willi syndrome. Clinical Endocrinology 
(Oxf). 2008;68:919–925.
122.  Whitman BY, Myers S, Carrel A, Allen D. The behavioral impact 
of growth hormone treatment for children and adolescents with 
Prader-Willi syndrome: a 2-year controlled study. Pediatrics. 
2002;109(2):E35.
123.  Myers SE, Whitman BY, Carrel AL, Moerchen V , Bekx MT, Allen DB. 
Two years of growth hormone therapy in young children with Prader-
Willi syndrome: physical and neurodevelopmental benefits. American 
Journal of Medical Genetics. 2007;143(5):443–448.
124.  Lee PD. Disease management of Prader-Willi syndrome. Expert 
Opinion on Pharmacotherapy. 2002;3(10):1451–1459.
125.  De Lind van Wijngaarden RF, Siemensma EP, Festen Da, et al. Efficacy 
and safety of long-term continuous growth hormone treatment in chil-
dren with Prader-Willi syndrome. Journal of Clinical Endocrinology 
and Metabolism. 2009;94(11):4205–4215.
126.  Festen DA, de Weerd AW, van den Bossche RA, Joosten K, Hoeve H, 
Hokken-Koelega AC. Sleep-related breathing disorders in prepubertal 
children with Prader-Willi syndrome and effects of growth hor-
mone treatment. Journal of Clinical Endocrinology Metabolism. 
2006;91(12):4911–4915.
127.  Miller J, Silverstein J, Shuster J, Driscoll DJ, Wagner M. Short-term 
effects of growth hormone on sleep abnormalities in Prader-Willi 
syndrome. Journal of Clinical Endocrinology Metabolism. 
2005;92(2):413–417.
128.  Scheimann AO, Butler MG, Gourash L, Cuffari C, Klish W. Critical 
analysis of bariatric procedures in Prader-Willi syndrome. Journal of 
Pediatric Gastroenterology and Nutrition. 2008;46(1):80–83.
129.  Dech B, Budow L. The use of fluoxetine in an adolescent with 
Prader-Willi syndrome. Journal of American Academy of Child Ado-
lescent Psychiatry. 1991;30:298–302.
130.  Hellings JA, Warnock JK. Self-injurious behavior and serotonin 
in  Prader-Willi  syndrome.  Psychopharmacology  Bulletin. 
1994;30(2):245–250.
131.  Murphy TK, Segarra A, Storch EA, Goodman WK. SSRI adverse 
events: how to monitor and manage. International Review of 
Psychiatry. 2008;20(2):203–208.
132.  Shapira NA, Lessig MC, Lewis MH, Goodman WK, Driscoll DJ. 
Effects of topiramate in adults with Prader-Willi syndrome. American 
Journal of Mental Retardation. 2004;109(4):301–309.
133.  Benjamin E, Buot-Smith T. Naltrexone and fluoxetine in Prader-Willi 
syndrome. Journal of American Academy of Child Adolescent 
Psychiatry. 1993;32:870–873.
134.  Jerome L. Prader-Willi and bipolar illness. Journal of American 
Academy of Child Adolescent Psychiatry. 1993;32(4):876–877.
135.  Warnock JK, Kestenbaum T. Pharmacologic treatment of severe skin-
picking behaviors in Prader-Willi syndrome. Two case reports. Archives 
of Dermatology. 1992;128(12):1623–1625.
136.  Kohn Y, Weizman A, Apter A. Aggravation of food-related behav-
ior in an adolescent with Prader-Willi syndrome treated with 
fluvoxamine and fluoxetine. International Journal of Eating Disorders. 
2001;30(1):113–117.